You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
15 October 2018 - - US-based biopharmaceutical company Aimmune Therapeutics, Inc. (NASDAQ: AIMT) has initiated a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients, the company said.
15 October 2018 - - US-based drug development company Karuna Pharmaceuticals, Inc, which is focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment, has initia...
15 October 2018 - - US-based The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele biotechnology and Pharmaceuticals to develop new single-domain nanoantibody therapies for the trea...
15 October 2018 - - The US Food and Drug Administration has granted Orphan Drug Designation for US-based biotechnology company X4 Pharmaceuticals' drug candidate, X4P-001-RD for the treatment of WHIM syndrome, a primary immunodeficiency disease ...
15 October 2018 - - US-based biotechnology company Genentech's Phase III KATHERINE study met its primary endpoint, showing Kadcyla (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (...
15 October 2018 - - US-based oncology drug developer Verastem, Inc., (NASDAQ: VSTM) has priced an offering of 5.00% convertible senior notes due 2048 through a registered direct offering, the company said.
The aggregate principal amount ...
The aggregate principal amount ...
15 October 2018 - United States-based Bristol-Myers Squibb and Compugen, a genomics-based drug and diagnostic discovery company, headquartered in Israel, have agreed to assess the safety and tolerability of the combination of Opdivo (nivolumab) and C...